Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study

In real life, ponatinib is a “niche-drug” reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates.